Sleep takes up almost one third of our life, yet many of its secrets remain unexplained. To penetrate the mystery, neuroscientists are trying to decipher some of the mechanisms of this basic biological function, so key to good health.
One of those neuroscientists is a Canadian: Université de Montréal (UdeM) professor Valérie Mongrain, holder of the Canada Research Chair in Sleep Molecular Physiology.
Her current project—examining a potential link between sleep and Alzheimer’s disease—is funded over five years by the Canadian Institutes of Health Research.
With UdeM professor Jonathan Brouillette, Mongrain said she’s “looking to identify biomarkers present at the onset of Alzheimer’s disease, by examining the effects of amyloid-beta oligomers on neurons and sleep.”
The scientific literature is clear: amyloid-beta oligomers accumulate in the brain one to two decades before Alzheimer’s disease is diagnosed, said Mongrain, who’s also involved in the Québec Sleep Research Network funded by the Fonds de recherche du Québec—Santé.
These oligomers are involved in the loss of connections—synapses—between neurons, notably in the hippocampus. This region of the brain is involved in sleep control and contributes to the so-called explicit memory through which people consciously remember things.
“Some of the first clinical symptoms we see in patients are disruptions in wakefulness and sleep,” said Mongrain. “But we don’t know to what extent oligomers are responsible for these alterations.”